Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 27.74%.

  • BioNexus Gene Lab's EBITDA Margin fell 163900.0% to 27.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.17%, marking a year-over-year decrease of 274000.0%. This contributed to the annual value of 15.52% for FY2024, which is 141300.0% up from last year.
  • Per BioNexus Gene Lab's latest filing, its EBITDA Margin stood at 27.74% for Q3 2025, which was down 163900.0% from 11.02% recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's EBITDA Margin registered a high of 18.99% during Q4 2023, and its lowest value of 102.9% during Q3 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 11.02% (2025), whereas its average is 12.87%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -874500bps in 2023, then surged by 915500bps in 2024.
  • BioNexus Gene Lab's EBITDA Margin (Quarter) stood at 3.95% in 2021, then surged by 115bps to 8.5% in 2022, then surged by 123bps to 18.99% in 2023, then plummeted by -322bps to 42.21% in 2024, then skyrocketed by 34bps to 27.74% in 2025.
  • Its EBITDA Margin was 27.74% in Q3 2025, compared to 11.02% in Q2 2025 and 25.79% in Q1 2025.